The SOHO Study Group is listed in the Acknowledgements section.
The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment
Article first published online: 20 MAY 2003
Acta Psychiatrica Scandinavica
Volume 107, Issue Supplement s416, pages 7–15, May 2003
How to Cite
Haro, J. M., Edgell, E. T., Frewer, P., Alonso, J., Jones, P. B. and on behalf of the SOHO Study Group (2003), The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatrica Scandinavica, 107: 7–15. doi: 10.1034/j.1600-0447.107.s416.4.x
This paper is one of a suite of papers reporting aspects of the Schizophrenia Outpatient Health Outcomes (SOHO) Study. The study and this publication were funded by Eli Lilly and Company Limited, Windlesham, Surrey, UK.
- Issue published online: 20 MAY 2003
- Article first published online: 20 MAY 2003
- antipsychotic agents;
- outcome assessment (health care);
Objective: To describe the baseline findings and study population of the Schizophrenia Outpatient Health Outcomes (SOHO) Study.
Method: The SOHO study is an ongoing, large, prospective, long-term observational study of schizophrenia treatment in 10 European countries. The study population consists of out-patients who initiate therapy or change to a new antipsychotic.
Results: A total of 1096 investigators enrolled 10 972 patients. Approximately 60% of patients were men and the mean age was 40 years. Patients treated with clozapine and more than one antipsychotic are more severely ill, patients receiving depot medications have a history of non-compliance, and patients receiving their first antipsychotic for schizophrenia are most likely to receive an atypical agent.
Conclusion: The SOHO study population appears to represent European out-patients with schizophrenia in whom a treatment decision is required. Baseline findings reflect European clinical practice with respect to patients treated with individual antipsychotics.